Skip to main content

PROTECT-C - genetic screening

One in every 20 cancers in women are caused by genetic defects that are passed down through families and are potentially preventable. However, 97% of women with these genetic defects remain unidentified. If found through testing, women can take measures to prevent breast, bowel, womb and ovarian cancer developing. They can also get screened regularly so that if they do develop cancer they are diagnosed at the earliest possible stage when more treatment options may be available, and survival is more likely.

Image representation of a DNA strand

“This critically important and exciting study can change the paradigm for implementing genetic testing in healthcare for patient and population benefit. This approach can prevent thousands more cancers than any current clinical strategy, saving the lives of many women.”

Queen Mary University of London, Professor of Gynaelogical Oncology

Yorkshire Cancer Research is funding a £3.8 million trial, led by Professor Ranjit Manchanda at Queen Mary University of London. The PROTECT-C trial will investigate the risks, benefits and feasibility of introducing testing for all women. Thousands of women living in Yorkshire will be offered tests to find out if they are at high risk of cancer as part of this new clinical trial. The findings could transform the way women, and their families, find out if they are at high risk of cancer, meaning they have a choice and can take steps to prevent cancer.

Interested in learning more about this genetic screening trial?

Sign up to our email mailing list to be among the first to know more about PROTECT-C, including how you might be able to take part. 

By filling in this form you're agreeing to hear from us by email. You can unsubscribe at any time. Please read our privacy policy below for information about how your data is used.


Professor Ranjit Manchanda

Queen Mary University of London